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Abstract
A cation- interaction between the ammonium group of an agonist and a conserved tryptophan termed TrpB is a near
universal feature of agonist binding to nicotinic acetylcholine receptors (nAChRs). TrpB is one of five residues that form
the aromatic box of the agonist binding site, and for the prototype agonists ACh and nicotine, only TrpB makes a
functional cation- interaction. We report that, in addition to TrpB, a significant cation- interaction is made to a
second aromatic, TyrC2, by the agonists metanicotine, TC299423, varenicline, and nornicotine. A common structural
feature of these agonists, and a distinction from ACh and nicotine, is a protonated secondary amine that provides the
cation for the cation- interaction. These results indicate a distinction in binding modes between agonists with subtly
different structures that may provide guidance for the development of subtype-selective agonists of nAChRs.
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Introduction
The neuronal nicotinic acetylcholine receptors (nAChRs)
are members of the Cys-loop ligand-gated ion channel
family and are established therapeutic targets for nicotine
addiction, as well as possible targets for Parkinson’s
disease, Alzheimer’s disease, pain, and other neural dis-
orders (Romanelli et al., 2007). The receptors are pentam-
ers, and 11 known subunits, 2-7,9,10 and 2-4, combine
to form distinct subtypes (Le Novère et al., 2002; Millar,
2003; Gotti et al., 2006; Zoli et al., 2015). The nAChR
binding site lies at the extracellular - interface, and it
contains an aromatic box motif that binds the cationic
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Significance Statement
The 42 nicotinic acetylcholine receptor (nAChR) binding site is made of several loops contributing five
aromatic residues. Here, we show four secondary ammonium agonists, TC299423, metanicotine, vareni-
cline, and nornicotine, make a cation- interaction with TyrC2 in addition to the canonical cation-
interaction with TrpB. The prototypical agonists acetylcholine (a quaternary ammonium), and nicotine (a
tertiary ammonium) only make a cation- interaction with TrpB. This result indicates a new binding mode
for agonists with only subtle structural differences and suggests that a more compact cation allows for
greater interaction with loop C in the binding site.
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moiety of the agonist through a cation- interaction (Fig.
1; Dougherty, 1996, 2013; Van Arnam and Dougherty,
2014). Five aromatic residues are contributed by four
loops, TyrA, Trp B, TyrC1, TyrC2, and TrpD (Corringer
et al., 2000). In many studies of ligands binding to
nAChRs, TrpB forms a functionally important cation-
interaction, while the other aromatics apparently play
other roles (Xiu et al., 2009; Blum et al., 2010, 2013;
Puskar et al., 2012; Tavares et al., 2012; Van Arnam and
Dougherty, 2014).
A major goal in nAChR research is to develop agonists
that target specific subtypes (Holladay et al., 1997; Quik
and Wonnacott, 2011; Dineley et al., 2015). For example,
the 42-containing subtypes are expressed throughout
the brain and are most associated with several aspects of
nicotine addiction (De Biasi and Dani, 2011). The 62-
containing subtypes have a more restricted distribution.
They occur on dopaminergic neurons, where they have
been associated with reward-related behavior and Parkin-
son’s disease, as well as on medial habenula neurons,
which play a role in aversive behavior (Quik and McIntosh,
2006; Jackson et al., 2013; Henderson et al., 2014; Zuo
et al., 2016). Finding agonists that meaningfully distin-
guish between the 42 and 62 interfaces is an un-
solved challenge, but metanicotine (rivanicline, TC-2403,
or RJR-2403) and TC299423 have been found to prefer-
entially activate 42- and 62-containing subtypes,
respectively (Drenan et al., 2008; Grady et al., 2010; Xiao
et al., 2011; Wall, 2015).
Previous analysis of TC299423 at 62 showed an
unusual binding pattern, in that the agonist does not make
a functional cation- interaction with TrpB or any other
aromatic box residue (Post et al., 2015); thus, a unique
binding mode may contribute to its subtype selectivity.
Here, TC299423 and other agonists were studied at the
more extensively characterized 42 receptor to see
whether the unusual binding pattern persists. Several ago-
nists were found to make cation- interactions with both
TrpB and TyrC2, and we show that this dual cation-
feature is a more general trend among secondary ammo-
nium agonists (Fig. 2) at 42.
Materials and Methods
Molecular biology
Rat 4 and 2 subunits were used as the basis for the
constructs. The L9’A mutation in the 4 M2 transmembrane
domain, at the gate of the channel, was incorporated to
amplify signal by shifting the stability of the channel par-
tially toward the active state. This 4L’A2 construct is
described as wild type and/or 42 throughout the report
for clarity in comparing noncanonical mutations made to
the binding site, which is over 60 Å away from the channel
gate. All constructs were in the pGEMhe vector, a cDNA
plasmid optimized for protein expression in Xenopus
oocytes. Site-directed mutagenesis was performed by PCR
Figure 1. A view of nicotine at the 42 binding site. The crystal structure of 42 (PDB 5KXI) on the left shows the aromatic box motif,
with each loop contributing to the binding site in a unique color and nicotine in gray. The schematic on the right details the hydrogen bond
(red) and cation- interaction (purple) interactions previously determined for nicotine with TrpB (4: 149), as well as how TyrC2 (4: 197)
could interact with other agonists. TyrA (4: 93), TyrC1(4: 190), and TrpD (2: 57) are shown in the crystal structure but omitted from the
schematic for clarity. An alignment of each loop contributing to the box in the human nAChR family is shown at the bottom.
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using the Stratagene QuikChange protocol, and primers
ordered from Integrated DNA Technologies. Circular
cDNA was linearized with SbfI (New England Biolabs) and
then transcribed in vitro using T7 mMessage mMachine
kit (Life Technologies), with a purification step after each
process (QIAGEN). Final concentrations were quantified
by UV spectroscopy.
Ion channel expression
Xenopus laevis oocytes (stage V to VI) were sourced
from both an institute facility and Ecocyte Bio Science.
Oocytes were injected with 50-nL solution containing ei-
ther 5- or 10-ng mRNA, injected in a 1:2 4:2 ratio to
control for a pure population of the (4L9’A)2(2)3 stoichi-
ometry. The alternative stoichiometry (4)3(2)2 has a
much lower EC50 due to the extra L9’A mutation. We
therefore avoided a mixed population containing both
stoichiometries. Cells were incubated 24-48 h at 18°C in
ND96 solution (96 mM NaCl, 2mM KCl, 1 mM MgCl2, and
5mM HEPES, pH 7.5) enriched with theophylline, sodium
pyruvate, and gentamycin.
Noncanonical amino acid incorporation
The cyanomethylester form of nitroveratryloxycarbonyl
(NVOC)-protected tryptophan and phenylalanine ana-
logues was coupled to dinucleotide dCA and enzymati-
cally ligated to UAG-suppressor 74-mer THG73 tRNACUA.
The product was verified by Matrix-assisted laser desorp-
tion/ionization (MALDI) time-of-flight mass spectrometry on
a 3-hydroxypicolinic acid matrix. The noncanonical amino
acid-coupled tRNA was deprotected by photolysis either
on a 500 W Hg/Xe arc lam, filtered with Schott WG-320
and UG-11 filters, or with an M365LP1 365 nm 1150 mW
LED lamp (Thor Labs) immediately before coinjection with
mRNA containing the UAG mutation at the site of interest.
mRNA and tRNA were typically injected in a 1:1 or 1:2
volume ratio in a total volume of 50 or 75 nL, respectively,
so that 25 ng of mRNA was injected per cell. In cases
where observed agonist-induced currents were low after
48-h incubation, likely due to low protein expression, a
second injection of mRNA and tRNA was performed after
24 h. The fidelity of noncanonical amino acid incorpora-
tion was confirmed at Trp with a wild-type recovery ex-
periment where tryptophan was loaded onto tRNA. If this
experiment yielded similar to EC50 to wild type, then the
cell incorporated the charged residue and nothing else.
This was accomplished with the Tyr sites by comparing
tRNA charged with Phe to a conventional Tyr-Phe muta-
tion. A read-through/reaminoacylation test served as a
negative control by injecting unacylated full-length 76-
mer tRNA. Lack of current proved no detectable reami-
noacylation at the suppression site.
Whole-cell electrophysiological characterization
(S)-nornicotine hydrochloride was purchased from Ma-
trix Scientific, while varenicline (Pfizer), metanicotine, and
TC299423 (Targacept) were generous gifts. Agonist-induced
currents were recorded in TEVC mode using the OpusX-
press 6000A (Molecular Devices) at a holding potential
of 60 mV in a running buffer of Ca2-free ND96, which
since 42 is Ca2 permeable, prevents interference from
Ca2-activated channels endogenous to the oocyte. Ago-
nists were prepared in Ca2-free ND96 and delivered to
cells via a 1-mL application over 15 s followed by a 2-min
Figure 2. The structures and electrostatic potential maps of acetylcholine and nicotine are shown here for comparison to the
secondary amine agonists and have been calculated with Hartree Fock 6-31G (shown on a scale of 10, red and more negative
electrostatic potential, to 150, blue and more positive electrostatic potential, kcal/mol).
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wash. For data from dose-response experiments were
normalized, averaged, and fit to the Hill equation using
Kaleidagraph (Synergy Software). In data tables, N is the
total number of oocytes analyzed, and cells from different
frogs on at least two different days were used for each
point. Fluorination plots are visualized here with Prism
(GraphPad Software). EC50 and Hill coefficient errors are
presented as SEM.
Results
Binding studies of TC299423 and metanicotine at
42
All studies here used the previously described (L9’A)2(2)3
receptor (Kuryatov et al., 2005; Nelson et al., 2003).
TC299423 was first probed for cation- interactions at
TrpB and TyrC2 (TyrA, TyrC1, and TrpD have never been
implicated in a cation- interaction). In these experiments,
the site of the aromatic residue of interest is mutated to a
TAG stop codon. mRNA made in vitro is injected into
Xenopus oocytes alongside a bioorthogonal tRNACUA that
has been chemically appended to the noncanonical
amino acid of interest. To probe for an agonist cation-
interaction, a series of residues with electron-withdrawing
groups that weaken the interaction is used. Typically,
fluorotryptophans (FnTrp) are used to probe Trp and fluo-
rophenylalanines (FnPhe) are used to probe Tyr (fluorinat-
ing tyrosine causes the phenol group to deprotonate at
physiologic pH). The endpoints of the two series, F4Trp
and F3Phe, are both thought to approximate a situation in
which the dominant electrostatic component of the
cation- interaction has been completely removed, allow-
ing a semiquantitative comparison of Trp and Tyr resi-
dues. Any change in binding is revealed by a changed
EC50 value, monitored by two-electrode voltage clamp
electrophysiology dose-response experiments. If the in-
teraction is weakened by these substitutions, EC50 corre-
spondingly increases. This change is visualized in so-
called fluorination plots of the log of the fold-shift in EC50
against the calculated gas-phase cation- interaction
strength.
At TrpB, TC299423 showed an increase in EC50 with
each additional fluorine substituent on the ring (Table 1),
but the maximum fold-shift in EC50 observed at F4Trp was
only 6.6-fold. While this is a modest loss of function, ACh
experiences a 66-fold loss of function at F4Trp in 42
(Xiu et al., 2009), there is nevertheless a linear trend in the
fluorination plot (Fig. 3). Thus, it can be said that TC299423
makes a functional, if modest, cation- interaction with
TrpB in 42.
TyrC2 was then probed for a cation- interaction with
TC299423 and showed an unexpected trend, with F3Phe
substitution resulting in a 30-fold increase in EC50. When
presented as a fluorination plot (Fig. 4), these results show a
linear trend, showing that in addition to a cation- interac-
tion with TrpB, TC299423 makes a functional, and energet-
ically more significant, cation- interaction at TyrC2.
Metanicotine, an isomer of nicotine in which the pyrro-
lidine ring has been opened, has antinociceptive effects in
mice and is more potent and efficacious than ACh at 42
receptors (Damaj et al., 1999; Papke et al., 2000). When
Table 1: TC299423
TrpB EC50 (M) nH Imax (A) Fold shift N
Trp 0.023  0.0009 1.4  0.06 0.22–1.46 1 15
F1Trp 0.043  0.0008 1.3  0.03 0.12–1.2 1.8 11
F2Trp 0.052  0.001 1.2  0.04 0.05–0.62 2.2 14
F3Trp 0.13  0.003 1.2  0.03 0.11–1.41 5.5 12
F4Trp 0.15  0.007 1.1  0.05 0.15–0.77 6.6 14
TyrC2 EC50 (M) nH Imax (A) Fold shift N
Phe 0.098  0.003 1.1  0.03 0.06–1.08 1 17
F1Phe 0.14  0.005 1.2  0.04 0.05–0.38 1.5 12
F2Phe 1.6  0.07 1.3  0.06 0.05–0.57 16 9
F3Phe 3.0  0.25 1.3  0.11 0.07–0.18 30 7
Figure 3. Fluorination plots of all the agonists tested in this report at TrpB in 42. The x-axis is the predicted M06/6-31G(d,p)
DFT-calculated energies between a sodium ion and each side chain (labeled) in the gas phase as described in Davis and Dougherty
(2015). The y-axis is the log of the fold-shift in EC50. Each agonist tested showed a linear trend and, therefore, demonstrated a
functional cation- interaction at TrpB, as previously seen with acetylcholine and nicotine. Data plotted for varenicline are from
Tavares et al. (2012).
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analyzed via a fluorination series at TrpB in 42, metani-
cotine displayed a functional cation- interaction, with a
linear fluorination plot and F4Trp resulting in a 25-fold shift
in EC50 (Table 2; Fig. 3). TyrC2 also shows a linear fluori-
nation plot, with the F3Phe mutation causing a 51-fold
shift relative to Phe (Fig. 4). TyrA was probed and showed
no meaningful changes in metanicotine EC50 on fluorina-
tion (Table 2; nicotine and ACh also showed no meaning-
ful shifts in EC50 at this site; Xiu et al., 2009). Thus,
metanicotine also forms dual, functional cation- interac-
tions at TrpB and TyrC2 in 42.
Both metanicotine and TC299423 are typical nicotinic
pharmacophores in that they have a cationic amine moi-
ety, a hydrogen bond donor associated with that amine,
and a hydrogen bond acceptor several angstroms away
(Blum et al., 2010). In contrast to the tertiary ammonium
nicotine and the quaternary ammonium ACh, metanico-
tine and TC299423 are both secondary ammonium ions.
Thus, to test whether this feature was associated with the
novel dual cation- interaction, additional secondary
amine agonists were analyzed.
Establishing a binding trend for secondary amines
Varenicline (Chantix) is a smoking cessation drug that is
thought to work by serving as a partial agonist to 42
(Coe et al., 2005a, 2005b) It has a secondary ammonium
Figure 4. Fluorination plots of all the agonists tested in this report at TyrC2 in 42. The x-axis is the predicted M06/6-31G(d,p)
DFT-calculated energies between a sodium ion and each side chain (labeled) in the gas phase as described in Davis and Dougherty
(2015). The y-axis is the log of the fold-shift in EC50. Each agonist tested shows a linear trend and, therefore, demonstrates a functional
cation- interaction with TyrC2, a result not previously seen with acetylcholine or nicotine.
Figure 5. Representative traces from dose-response experiments with a variety of agonists, noncanonical amino acid substitutions,
and Imax values.
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as its cationic center. This drug has previously been shown
to form a cation- interaction at TrpB in 42 (Tavares et al.,
2012), with a 23-fold shift in EC50 at F4Trp (Table 3; Fig. 3),
but had not been analyzed at TyrC2.
Nonsense-suppression-based fluorination studies were
conducted for varenicline at TyrC2 as discussed above.
The corresponding fluorination plot shows a linear trend
with a 19-fold shift for F3Phe, confirming that varenicline
makes a cation- interaction with TyrC2 in 42 (Table 3;
Fig. 4).
Varenicline was the third secondary ammonium agonist
to demonstrate functional cation- interactions with both
TrpB and TyrC2 in 42. To support the notion that a dual
cation- interaction is associated with secondary ammo-
nium agonists in 42, we transformed nicotine, which
makes a single cation- interaction at TrpB, into a sec-
ondary ammonium. Nornicotine, nicotine that has been
demethylated at the pyrrolidine N, is a natural component
of tobacco that is a precursor to the well-documented
carcinogen N’-nitrosonicotine that is a by-product of the
curing process.(Siminszky et al., 2005)
Nornicotine is much less potent than its methylated
analog, with an EC50 of 1.8 M, a 20-fold greater value
than for nicotine. This agonist also elicits much smaller
currents; however, the waveform shapes (Fig. 5) are con-
sistent with other agonists, and a clear dose-response
relation is present. The fluorination plot of nornicotine at
TrpB shows a cation- interaction, with F4Trp resulting in
a 27-fold shift in EC50, demonstrating a functionally im-
portant cation- interaction (Table 4; Fig. 3). Results at
TyrC2 show the same type of trend seen for other sec-
ondary ammonium agonists analyzed in this report, with a
linear fluorination plot and a 11-fold loss of function for
F3Phe (Table 4; Fig. 4).
Discussion
Structure-function studies of four different agonists
with distinct overall structures but a common secondary
ammonium moiety have established a functional cation-
interaction with both TrpB and TyrC2 in 42 nAChRs.
Nornicotine forms a cation- interaction with TyrC2, but
nicotine, which only differs from nornicotine by being a
tertiary rather than secondary ammonium, does not. This
nicotine/nornicotine comparison in particular presents a
compelling case that the dual cation- interaction is a
consequence of the secondary ammonium group of se-
lect agonists at 42.
The significance of TrpB in agonist binding to nAChRs
remains a central tenet of the pharmacology of this sys-
tem. In a cation- interaction, the aromatic ring of Trp is a
stronger binding site that those of Tyr or Phe, regardless
of the nature of the cation, but Tyr and Phe can certainly
make strong cation- interactions (Davis and Dougherty,
2015). Early studies focused on ACh and nicotine and
found that only TrpB showed a strong response to fluori-
nation. We have now found that four other agonists show,
in addition to TrpB, a significant response to fluorination
at TyrC2. These four are structurally diverse but share a
common feature of being a secondary ammonium. The
implication is clear that the more compact secondary
ammonium is able to establish an additional interaction
compared with the bulkier quaternary (ACh) or tertiary
(nicotine) systems.
Two studies of the primary ammonium agonist GABA at
pentameric receptors, one at the RDL insect GABA re-
ceptor and one at the prokaryotic Erwinia ligand-gated ion
channel (ELIC) receptor, show that this primary ammo-
nium agonist makes functionally important cation- inter-
actions to the aromatics at positions B and C2 (Lummis
et al., 2005; Spurny et al., 2012). Again, a more compact
agonist can make a dual cation- interaction. A recent
computational study of the AChBP aromatic box suggests
that the side chains of each aromatic box residue can
contribute to the overall cation- binding energy in the
ACh-AChBP complex (Davis and Dougherty, 2015). How-
ever, from a functional perspective, only TrpB is univer-
Table 2: Metanicotine
TrpB EC50 (M) nH Imax (A) Fold shift N
Trp 0.64  0.02 1.3  0.0 0.08–0.89 1 13
F1Trp 0.79  0.02 1.4  0.0 0.12–0.80 1.2 16
F2Trp 3.6  0.1 1.5  0.1 0.15–0.56 5.6 14
F3Trp 13  1 1.6  0.1 0.07–0.30 20 12
F4Trp 16  2 1.3  0.1 0.03–0.11 25 12
TyrA EC50 (M) nH Imax (A) Fold shift N
Phe 19  5 1.1  0.2 0.02–0.16 1 7
F3Phe 17  2 1.3  0.1 0.01–0.03 0.9 6
TyrC2 EC50 (M) nH Imax (A) Fold shift N
Phe 0.41  0.03 1.2  0.07 0.06–2.78 1 17
F1Phe 0.86  0.06 1.2  0.08 0.04–0.07 2.1 11
F2Phe 11  1 0.6  0.1 0.03–0.13 27 8
F3Phe 21  1 1.4  0.2 0.04–0.24 51 12
Table 3: Varenicline
TrpB EC50 (M) nH Fold shift N
Trp 0.0024  0.0001 1.2  0.1 1 15
F1Trp 0.0057  0.0002 1.2  0.1 2.4 11
F2Trp 0.0057  0.0021 1.2  0.1 2.4 14
F3Trp 0.027  0.001 1.3  0.1 11 12
F4Trp 0.056  0.005 1.1  0.1 23 14
TyrC2 EC50 (M) nH Imax (A) Fold shift N
Phe 0.0014  0.0002 1.3  0.14 0.04–0.14 1 10
F1Phe 0.0020  0.00009 1.5  0.09 0.02–0.08 1.4 8
F2Phe 0.011  0.00097 1.2  0.11 0.02–0.1 8.1 12
F3Phe 0.027  0.0016 1.1  0.06 0.02–0.09 19 8
Table 4: Nornicotine
TrpB EC50 (M) nH Imax (A) Fold shift N
Trp 1.7  0.1 1.3  0.1 1.33–9.37 1 13
F1Trp 4.6  0.2 1.3  0.1 0.27–0.9 2.8 16
F2Trp 11  0.7 1.3  0.1 0.04–0.11 6.4 8
F3Trp 26  2 1.5  0.1 0.05–1.28 16 16
F4Trp 44  4 1.2  0.1 0.95–1.51 27 8
TyrC2 EC50 (M) nH Imax (A) Fold shift N
Phe 3.3  0.3 1.2  0.1 0.02–1.42 1 15
F1Phe 5.5  0.3 1.0  0.1 0.04–0.11 1.7 11
F2Phe 31  3 1.2  0.1 0.03–0.26 9.6 10
F3Phe 35  2 1.4  0.1 0.02–0.14 11 12
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sally important, with TyrC2 being identified here as
contributing in some, but not all, cases.
A popular model for nAChR gating proposes that loop C
moves on agonist binding so as to clamp down on the
agonist and more clearly define the aromatic box (Wang
et al., 2009). This movement of loop C is proposed to be
a key functional feature of the gating mechanism. It may
be that with the less bulky secondary ammonium ago-
nists, loop C is able to move closer to the agonist. This
larger motion by loop C leads to a closer contact between
TyrC2 and the agonist, enabling a cation- interaction and
making TyrC2 responsive to fluorination. AChBP structures
with varenicline versus nicotine bound do not show a mean-
ingful difference in the position of loop C, but AChBP did not
evolve to undergo a gating process and likely undergoes
minimal conformational changes when binding small mole-
cules (Celie et al., 2004; Rucktooa et al., 2012).
In summary, we have found a distinction in the binding
mode of agonists at the 42 nAChR. The natural agonist
ACh and the prominent component of tobacco nicotine
both make a cation- interaction to TrpB, along with other
hydrogen bonding interactions. In contrast, four agonists
that share a common feature of being secondary ammo-
nium ions make a dual cation- interaction to TrpB and
TyrC2. This pattern may be unique to the 42 subtype,
as it was not reported for TC299423 at the 62 subtype
(Post et al., 2015). Further studies of other agonists and
other subtypes could provide valuable guidance in de-
signing more subtype-selective activators of nAChRs.
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